Searchable abstracts of presentations at key conferences in endocrinology

ea0099p31 | Adrenal and Cardiovascular Endocrinology | ECE2024

Blood pressure changes during smoking cessation on dulaglutide and placebo treatment – a secondary analysis of the randomized, double-blind, placebo-controlled SKIP trial

Julia Beck , Hasenbohler Flavia , Lengsfeld Sophia , Burkard Thilo , Meienberg Andrea , Jeanloz Nica , Vukajlovic Tanja , Bologna Katja , Bathelt Cemile , Vogt Deborah , Werlen Laura , Christ-Crain Mirjam , Winzeler Bettina

Objective: Smoking is an established major risk for atherosclerosis and cardiovascular mortality. However, the impact of smoking cessation on blood pressure remains controversial. Despite strong evidence linking smoking cessation to reduced cardiovascular risk, conflicting studies suggest potential increases in blood pressure after smoking cessation. Post cessational weight gain may contribute to these confliciting findings. We have recently shown that the glucagon-like peptid...

ea0081p76 | Diabetes, Obesity, Metabolism and Nutrition | ECE2022

Glucagon-like peptide-1 analogues: a new way to quit smoking? SKIP – a randomised controlled study

Lengsfeld Sophia , Burkard Thilo , Meienberg Andrea , Jeanloz Nica , Vukajlovic Tanja , Bologna Katja , Steinmetz Michelle , Sailer Clara , Coynel David , Vogt Deborah R , Hemkens Lars G. , Speich Benjamin , Kuhne Jill , Baur Fabienne , Lutz Linda , Bathelt Cemile , Zanchi Davide , Christ-Crain Mirjam , Winzeler Bettina

Background: Cigarette smoking is the leading preventable cause of premature death. Smoking cessation is one of the central goals in medicine, but despite dedicated programs, quit rates remain low due to barriers such as nicotine withdrawal syndrome or post-cessation weight gain. Glucagon-like peptide-1 (GLP-1) analogues reduce energy intake and body weight and seem to modulate addictive behavior. These GLP-1 properties are of major interest in the context of smoking cessation....